← Back to Search

Surgical Cohort for Brain Tumor

N/A
Waitlist Available
Led By Karisa Schreck, MD, PhD
Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1
Awards & highlights

Summary

This is a surgical biospecimen collection study. The purpose of this study is to understand how much of two drugs (dabrafenib and trametinib) are able to penetrate brain tumors and turn off the RAF signaling pathway. This is important because these drugs are currently FDA approved for other tumors and may have efficacy in brain tumors with the BRAF V600E mutation.

Eligible Conditions
  • Brain Tumor
  • Glioblastoma
  • Pleomorphic Xanthoastrocytoma
  • BRAF Mutation

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Concentration of dabrafenib in brain tumor
Concentration of trametinib in brain tumor

Trial Design

1Treatment groups
Experimental Treatment
Group I: Surgical CohortExperimental Treatment1 Intervention
Blood, cerebrospinal fluid, and tumor tissue will be obtained from each participant on this arm.

Find a Location

Who is running the clinical trial?

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
563 Previous Clinical Trials
33,321 Total Patients Enrolled
Musella FoundationUNKNOWN
1 Previous Clinical Trials
10 Total Patients Enrolled
Karisa Schreck, MD, PhDPrincipal InvestigatorJohns Hopkins School of Medicine
~0 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top